Sihuan Pharmaceutical Holdings Group (SEHK:460) Looks Pricey On 2026 Earnings GuidanceSimplywall·Jul 28 at 06:28 AM00460-3.31%
Sihuan Pharmaceutical Updates Bermuda Registered Office AddressTip Ranks·Jul 26 at 11:38 PM00460-3.31%
Sihuan Pharmaceutical Flags 217% Profit Surge on Medical Aesthetics and Portfolio GainsTip Ranks·Jul 26 at 11:08 PM00460-3.31%
Sihuan Pharmaceutical Holdings Group (SEHK:460) Following Phase III Trial Progress Is The Stock Too PriceySimplywall·Jul 3 at 07:03 AM00460-3.31%
Sihuan’s Xuanzhu Wins NMPA NDA Acceptance for New Reflux Esophagitis Use of AnaprazoleTip Ranks·Jun 29 at 11:38 PM00460-3.31%02575-0.36%
Xuanzhu Biopharma says NMPA accepts NDA for anaprazole sodium in reflux esophagitisPUBT·Jun 29 at 11:05 PM02575-0.36%
Sihuan Pharmaceutical Shareholders Approve All AGM Resolutions and Capital MandatesTip Ranks·Jun 26 at 04:14 AM00460-3.31%
Sihuan Pharmaceutical shareholders approve RMB 0.96 cent final dividend for 2025PUBT·Jun 26 at 03:43 AM00460-3.31%
Xuanzhu Biopharma Advances Anaprazole into Phase III Trial for H. pylori EradicationTip Ranks·Jun 21 at 05:38 AM02575-0.36%
Sihuan Pharma enrolls first patient in Phase III trial of anaprazole-based H. pylori eradication therapyPUBT·Jun 21 at 11:05 PM00460-3.31%
Sihuan’s Xuanzhu Biopharm Completes Full H Share Circulation in Hong KongTip Ranks·May 12 at 04:40 AM00460-3.31%02575-0.36%
Sihuan’s NG-350A Shows Promising Early Results in Rectal Cancer TrialTip Ranks·Apr 20 at 04:09 AM00460-3.31%
Sihuan’s Xuanzhu Unit Posts Strong Phase III Lung Cancer Data for ALK Inhibitor DirozalkibTip Ranks·Apr 19 at 11:08 PM00460-3.31%02575-0.36%
Xuanzhu Biopharm Wins Green Light for Phase III Anaprazole Trial in H. pyloriTip Ranks·Apr 14 at 05:40 PM02575-0.36%5606000.00%
